HomeCompareDWMNF vs JNJ

DWMNF vs JNJ: Dividend Comparison 2026

DWMNF yields 1.59% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DWMNF wins by $24.8K in total portfolio value
10 years
DWMNF
DWMNF
● Live price
1.59%
Share price
$63.06
Annual div
$1.00
5Y div CAGR
43.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55.1K
Annual income
$12,732.43
Full DWMNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DWMNF vs JNJ

📍 DWMNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDWMNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DWMNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DWMNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DWMNF
Annual income on $10K today (after 15% tax)
$134.87/yr
After 10yr DRIP, annual income (after tax)
$10,822.57/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DWMNF beats the other by $6,836.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DWMNF + JNJ for your $10,000?

DWMNF: 50%JNJ: 50%
100% JNJ50/50100% DWMNF
Portfolio after 10yr
$42.7K
Annual income
$8,710.92/yr
Blended yield
20.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DWMNF
No analyst data
Altman Z
2.8
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DWMNF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDWMNFJNJ
Forward yield1.59%2.13%
Annual dividend / share$1.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR43.6%28%
Portfolio after 10y$55.1K$30.3K
Annual income after 10y$12,732.43$4,689.40
Total dividends collected$31.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DWMNF vs JNJ ($10,000, DRIP)

YearDWMNF PortfolioDWMNF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,928$227.86$10,592$272.30+$336.00DWMNF
2$12,027$334.17$11,289$357.73+$738.00DWMNF
3$13,362$493.58$12,123$472.89+$1.2KDWMNF
4$15,034$735.97$13,141$629.86+$1.9KDWMNF
5$17,197$1,111.25$14,408$846.81+$2.8KDWMNF
6$20,107$1,705.99$16,021$1,151.60+$4.1KDWMNF
7$24,192$2,676.93$18,122$1,588.22+$6.1KDWMNF
8$30,207$4,322.36$20,930$2,228.20+$9.3KDWMNF
9$39,565$7,243.36$24,792$3,191.91+$14.8KDWMNF
10$55,067$12,732.43$30,274$4,689.40+$24.8KDWMNF

DWMNF vs JNJ: Complete Analysis 2026

DWMNFStock

Dowa Holdings Co., Ltd. engages in the environmental management and recycling, nonferrous metals, electronic materials, metal processing, and heat treatment businesses worldwide. The company's Environmental Management & Recycling segment offers intermediate waste treatment, controlled landfilling, and soil remediation services; metal, household appliance, and automobile recycling services; consulting on environmental matters; and environmental logistics services. Its Nonferrous Metals segment produces and sells gold, silver, copper, lead, zinc, zinc alloys, palladium, rhodium, tin, antimony, nickel sulfate, bismuth, indium, platinum, tellurium, and sulfuric acid. The company's Electronic Materials segment offers high-purity materials, GaAs substrate wafers, and light-emitting diodes, as well as silver, copper, metal, carrier, and ferrite powders. Its Metal Processing segment provides copper, brass, copper and nickel alloy strips, reflow tin plated strips, brass rods, forged brass products, precious metal plating products, and metal-ceramics substrates. The company's Heat Treatment segment is involved in the design, manufacture, and maintenance of various types of industrial furnaces and ancillary equipment, as well as heat and surface treatment. The company also engages in real estate leasing, plant construction, civil engineering and construction work, office administration services, and technological development. The company was formerly known as Dowa Mining Co., Ltd. and changed its name to Dowa Holdings Co., Ltd. in October 2006. Dowa Holdings Co., Ltd. was founded in 1884 and is headquartered in Tokyo, Japan.

Full DWMNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DWMNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DWMNF vs SCHDDWMNF vs JEPIDWMNF vs ODWMNF vs KODWMNF vs MAINDWMNF vs ABBVDWMNF vs MRKDWMNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.